| Prev Close | 270.21 |
| Day Low/High | 264.35 / 270.37 |
| 52 Wk Low/High | 223.25 / 468.55 |
Biogen Inc. (BIIB)
264.80
NASDAQ
| Exchange | NASDAQ |
| Shares Outstanding | 146.89B |
| Market Cap | 39.69B |
| P/E Ratio | 8.89 |
| Div & Yield | N.A. (N.A) |
Latest News
Bearish Bets: 2 Nasdaq Stocks You Should Consider Shorting This Week
These recently downgraded names are displaying both quantitative and technical deterioration.
Real Money Post Industrial Average Outperforms for the Quarter
RMPIA for the September-ending quarter is up .2%, outperforming most of the major market indexes. Let's dig in.
There's Good News for 3 Biotech Names
And It comes after one of the best days of the year for the biotech sector.
Jim Cramer: Why Hasn't the Government Pushed for Mass Vaccination?
Incompetence, omissions and even outright lies have categorized this federal attempt to 'stem' the pandemic.
Jim Cramer: This Moment Is One of the Toughest I Have Seen in Corporate America
The stock market's rise might have ended after the cliff, not before it.
Crypto Pep Rally, S&P Wonder Line, Minerd Unmuted, Chip Keepers, Trading Moderna
Small-caps and mid-caps are still picking first downs on every play, storming back from a badly oversold condition that has just about normalized.
Jim Cramer: It's a Jailbreak and the Stocks Are Busting Out
This market is moving in so many areas that you have to marvel at how it's even possible -- even if the Russell Rebalancing could change all that on Friday.
Rotation and Late-Day Strength Cover Up Mixed Action Underneath
Odd mix of moves precedes one of the most important Fed meetings in a while.
2 Small Biotech Stocks That Could See Big Gains Ahead
BioXcel Therapeutics and Albiero Pharma have promising prospects based on drugs in their pipelines.
Biogen's Japanese Partner on Alzheimer's Drug Set for Gains
Eisai is working on another promising drug candidate to combat Alzheimer's disease, and will benefit from a split of the profits for Aduhelm.
Updating Our Biogen Targets as It Soars on Alzheimer Drug Approval
Traders who went long BIIB on our April recommendation should continue to hold those shares.
Biogen Starts to Make Its Upside Move as Decision on Alzheimer's Drug Awaits
The drugmaker's charts are pointing to higher ground for its shares as a regulatory decision on its Alzheimer's drug aducanumab is at hand.
The Hour Glass Phenomena, Oh Canada, Portfolio Haircut, Earth Day, ESG Investing
Canada made the developed world's first moves toward normalizing monetary policy coming out of the pandemic, despite the fact that Canada does not seem to be flattening its own curve.
Biogen's Charts Are Ready for an Upside Breakout
Here's our first price objective.
Shock & Awe Markets, Bank Stocks, Apple's Debt Move, Trading Amazon, ServiceNow
Right off the top, the bubble has burst for the 'short squeeze' names such as GameStop and AMC Entertainment.
Real Money Post Industrial Average Feels January Chill
The RMPIA easily outpaced the main indexes for 2020, but slipped 1.7% last month.
Real Money Post Industrial Average Bests Most Major Indexes in 2020
As we enter the new year, there's little time to reflect on RMPIA's strong performance. Now, it's all eyes on the 12 months ahead of us.
Real Money Post Industrial Average Climbs 9.5% Over November
The RMPIA also tops other indexes for year, shooting ahead 29%.
Bearish Bets: 2 Biotech Stocks You Should Consider Shorting This Week
These names are displaying both technical and quantitative deterioration.
Real Money Post Industrial Average Rises 21% Year to Date
The average declined in October, but it was less than that hit took by the major indexes.
The Market Is Shrugging Off the Political News
And that is helping to create fear of missing out.
'Inside Day', Electoral Risk, Banking Stocks, Stimulus Immediately Needed
There is a presidential debate on Thursday. The market is being forced to adjust for renewed potential uncertainty.
Immatics Is a Bit Boy Who Cried Wolf
This is the type of chart that will grab the attention of momentum traders.
Veeva and RedHill: 2 Stocks to Consider as They Team Up to Battle Covid-19
RedHill Biopharma has adopted 'Veeva Vault CDMS', Veeva's modern cloud platform.
2 Biotech Stocks to Buy on Solid Q2 Results
Covid-19 has had a big impact on this sector, but these names have strong catalysts going into the next quarter.
